Cite
Kumamoto T, Goto H, Ogawa C, et al. Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. Int J Hematol. 2021;113(2):308-309doi: 10.1007/s12185-020-03077-4.
Kumamoto, T., Goto, H., Ogawa, C., Hori, T., Deguchi, T., Araki, T., Saito, A. M., Manabe, A., Horibe, K., & Toyoda, H. (2021). Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. International journal of hematology, 113(2), 308-309. https://doi.org/10.1007/s12185-020-03077-4
Kumamoto, Tadashi, et al. "Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group." International journal of hematology vol. 113,2 (2021): 308-309. doi: https://doi.org/10.1007/s12185-020-03077-4
Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, Saito AM, Manabe A, Horibe K, Toyoda H. Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. Int J Hematol. 2021 Feb;113(2):308-309. doi: 10.1007/s12185-020-03077-4. PMID: 33484418.
Copy
Download .nbib